Zitong Financial APP learned that Credit Suisse released a research report that maintained the "outperform" rating of Platinum Pharmaceuticals-B (02142) because it believed that the group was a differentiated biotech company with its own antibody platform to provide power for internal drug pipelines. raise the 2022-24 earnings per share forecast of 14.1%, 2.6% and 1.5%, with the target price raised from HK $7 to HK $7.6. As of 09:38, it was up 4.43% to quote HK $4.24, with a turnover of 5.4924 million.
According to the report, Heplatinum announced an external licensing agreement with AstraZeneca PLC (AstraZeneca) for preclinical bispecific antibody (bsAb) HBM7022. HBM7022 is a tumor associated antigen (Claudin18.2) targeted at tumor cells and CD3 on T cells, which selectively kills tumor cells.
Credit Suisse pointed out that this authorized transaction not only shows AstraZeneca PLC's interest in the field of bsAb, but also validates the antibody platform of Platinum Pharmaceutical. In addition, at least two additional preclinical bsAb of Platinum Pharmaceuticals have been disclosed and are under development, providing opportunities for further external authorization.